InnovAge (INNV) Competitors $5.26 -0.04 (-0.75%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends INNV vs. VCYT, LFST, PACS, CON, PRVA, ARDT, ADUS, NHC, WGS, and FTREShould you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include Veracyte (VCYT), LifeStance Health Group (LFST), PACS Group (PACS), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), Ardent Health Partners (ARDT), Addus HomeCare (ADUS), National HealthCare (NHC), GeneDx (WGS), and Fortrea (FTRE). These companies are all part of the "healthcare" industry. InnovAge vs. Veracyte LifeStance Health Group PACS Group Concentra Group Holdings Parent Privia Health Group Ardent Health Partners Addus HomeCare National HealthCare GeneDx Fortrea InnovAge (NASDAQ:INNV) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking. Do analysts recommend INNV or VCYT? InnovAge currently has a consensus price target of $6.50, suggesting a potential upside of 23.57%. Veracyte has a consensus price target of $41.00, suggesting a potential upside of 14.08%. Given InnovAge's higher possible upside, research analysts plainly believe InnovAge is more favorable than Veracyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InnovAge 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Veracyte 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has more volatility and risk, INNV or VCYT? InnovAge has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Does the media prefer INNV or VCYT? In the previous week, Veracyte had 11 more articles in the media than InnovAge. MarketBeat recorded 12 mentions for Veracyte and 1 mentions for InnovAge. Veracyte's average media sentiment score of 0.75 beat InnovAge's score of 0.43 indicating that Veracyte is being referred to more favorably in the news media. Company Overall Sentiment InnovAge Neutral Veracyte Positive Is INNV or VCYT more profitable? InnovAge has a net margin of -2.03% compared to Veracyte's net margin of -2.18%. Veracyte's return on equity of 3.02% beat InnovAge's return on equity.Company Net Margins Return on Equity Return on Assets InnovAge-2.03% -5.68% -2.99% Veracyte -2.18%3.02%2.80% Do institutionals and insiders believe in INNV or VCYT? 12.3% of InnovAge shares are owned by institutional investors. 1.4% of InnovAge shares are owned by company insiders. Comparatively, 1.3% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor INNV or VCYT? Veracyte received 441 more outperform votes than InnovAge when rated by MarketBeat users. Likewise, 73.26% of users gave Veracyte an outperform vote while only 0.00% of users gave InnovAge an outperform vote. CompanyUnderperformOutperformInnovAgeOutperform VotesNo VotesUnderperform Votes4100.00% VeracyteOutperform Votes44173.26% Underperform Votes16126.74% Which has stronger valuation & earnings, INNV or VCYT? InnovAge has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnovAge$763.85M0.93-$21.34M-$0.12-43.83Veracyte$361.05M7.71-$74.40M-$0.15-239.60 SummaryVeracyte beats InnovAge on 10 of the 18 factors compared between the two stocks. Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Get InnovAge News Delivered to You Automatically Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INNV vs. The Competition Export to ExcelMetricInnovAgeHealth services IndustryMedical SectorNASDAQ ExchangeMarket Cap$712.49M$649.49M$5.15B$8.74BDividend YieldN/A1.96%5.18%4.08%P/E Ratio-43.8326.3866.6713.57Price / Sales0.934.311,276.8487.67Price / CashN/A25.4739.7035.24Price / Book2.642.876.475.93Net Income-$21.34M-$10.72M$119.73M$225.73M7 Day Performance-12.33%-4.03%-5.13%-1.34%1 Month Performance-11.89%-1.30%-2.71%1.15%1 Year Performance-8.04%337.04%31.08%24.02% InnovAge Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INNVInnovAge1.0183 of 5 stars$5.26-0.8%$6.50+23.6%-4.6%$712.49M$763.85M-43.832,350VCYTVeracyte4.5637 of 5 stars$35.94-3.0%N/A+45.4%$2.79B$361.05M-239.60790Analyst ForecastNews CoverageHigh Trading VolumeLFSTLifeStance Health Group2.033 of 5 stars$7.14-1.2%N/A+16.7%$2.73B$1.21B-27.469,325PACSPACS Group3.4438 of 5 stars$17.41-5.5%N/AN/A$2.65B$3.11B0.0032,433News CoverageCONConcentra Group Holdings ParentN/A$20.53+0.8%N/AN/A$2.61B$1.84B0.0011,000PRVAPrivia Health Group3.5231 of 5 stars$21.20-2.3%N/A-7.3%$2.54B$1.72B212.021,102Positive NewsARDTArdent Health PartnersN/A$16.61-6.7%N/AN/A$2.37B$5.41B0.0024,200Analyst ForecastAnalyst RevisionNews CoverageADUSAddus HomeCare4.7342 of 5 stars$119.78-1.9%N/A+39.4%$2.17B$1.06B27.4134,846Analyst ForecastPositive NewsNHCNational HealthCareN/A$125.86-1.0%N/AN/A$1.94B$1.23B15.7713,123Dividend AnnouncementAnalyst UpgradePositive NewsWGSGeneDx1.4367 of 5 stars$68.43-7.2%N/A+4,555.1%$1.88B$267.23M-22.001,200Positive NewsFTREFortrea3.2974 of 5 stars$19.34-4.3%N/A-40.4%$1.73B$3.11B-5.6518,000Earnings Report Related Companies and Tools Related Companies VCYT Competitors LFST Competitors PACS Competitors CON Competitors PRVA Competitors ARDT Competitors ADUS Competitors NHC Competitors WGS Competitors FTRE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INNV) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InnovAge Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share InnovAge With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
